Tracking Alzheimer’s treatment for Medicare patients in early stages
Part of Mental health clinical trials.
This study tracks how well a certain type of Alzheimer’s treatment works for people on Medicare who are in the early stages of the disease. The goal is to collect real-world information about the drug’s benefits and risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of mild cognitive impairment or mild dementia caused by Alzheimer’s disease.
- Your brain must show signs of amyloid buildup, which is a hallmark of Alzheimer’s.
- You must be enrolled in Medicare (the U.S. federal health insurance program).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests antibody treatments that target amyloid plaques in the brain for people with mild memory or thinking problems. It may help determine if you are a candidate for these new drugs and monitors your safety through regular scans and checkups.
This trial tests whether a monoclonal antibody drug can help people with early Alzheimer's disease or mild cognitive impairment. The drug targets amyloid plaques in the brain, which are detected using a special PET scan before treatment.
This study tests whether using a stronger MRI scanner can help make antibody treatments for early Alzheimer's disease work better. If you are already eligible for and starting such a treatment, this study may help track how well it's working.
This study tests whether human stem cells, combined with your existing Alzheimer's medication (Leqembi or Kisunla), can help slow memory loss and improve daily functioning in people with mild cognitive impairment or early Alzheimer's. You would receive a stem cell infusion as an add-on to your current treatment.
This study tests a sequence of treatments to see if they can help people with Alzheimer's disease or mild cognitive impairment. It aims to slow down memory decline and improve daily function.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
Hear when a new Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.